# Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

> **NCT03894007** · PHASE2 · TERMINATED · sponsor: **Renske Altena** · enrollment: 6 (actual)

## Conditions studied

- Early-stage Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Atezolizumab
- **DRUG:** Trastuzumab emtansine
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03894007
- **Lead sponsor:** Renske Altena
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-23
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Security and effect data from another ongoing study.
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03894007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03894007, "Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03894007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*